Liquidia Corporation (LQDA)
NASDAQ: LQDA · IEX Real-Time Price · USD
13.17
+0.32 (2.49%)
At close: May 1, 2024, 4:00 PM
13.15
-0.02 (-0.15%)
After-hours: May 1, 2024, 7:53 PM EDT
Liquidia Revenue
In the year 2023, Liquidia had annual revenue of $17.49M with 9.75% growth. Revenue in the quarter ending December 31, 2023 was $4.53M, a -15.47% decrease year-over-year.
Revenue (ttm)
$17.49M
Revenue Growth
+9.75%
P/S Ratio
57.26
Revenue / Employee
$120,607
Employees
145
Market Cap
1.00B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 17.49M | 1.55M | 9.75% |
| Dec 31, 2022 | 15.94M | 3.08M | 23.98% |
| Dec 31, 2021 | 12.85M | 12.11M | 1,637.77% |
| Dec 31, 2020 | 739.63K | -7.33M | -90.84% |
| Dec 31, 2019 | 8.07M | 5.37M | 198.20% |
| Dec 31, 2018 | 2.71M | -4.55M | -62.70% |
| Dec 31, 2017 | 7.26M | -5.96M | -45.08% |
| Dec 31, 2016 | 13.22M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alignment Healthcare | 1.82B |
| Innoviva | 310.46M |
| Standard BioTools | 106.34M |
| Immatics | 60.00M |
| Arcutis Biotherapeutics | 59.61M |
| Silence Therapeutics | 32.12M |
| Bicycle Therapeutics | 26.98M |
| Abivax | 5.13M |
LQDA News
- 4 weeks ago - Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder - GlobeNewsWire
- 7 weeks ago - Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 - GlobeNewsWire
- 2 months ago - United Therapeutics starts litigation with FDA for allowing Liquidia's drug application - Reuters
- 3 months ago - Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress - GlobeNewsWire
- 3 months ago - US FDA extends review for Liquidia's inhaled blood pressure drug - Reuters
- 3 months ago - Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder - GlobeNewsWire